- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02774512
Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer (ZAK-0)
Phase 0 Study Aiming at Identifying Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
Descripción general del estudio
Descripción detallada
Tipo de estudio
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Bordeaux, Francia, 33076
- Institut Bergonie
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent signed prior any study-related procedures.
- Histological diagnosis of colon cancer.
- Performance status ECOG 0, 1, or 2.
- Physical status score ASA 1 or 2.
- Patient without metastasis.
- No previous anti-cancer treatment for colon cancer.
- Age ≥ 18.
- Preoperative imaging: thorax-abdominal-pelvis CT scan within 2 months.
- Colonoscopy and biopsies to determine ZAK-0 expression level.
- Scheduled beginning of the treatment 7 days before surgical procedure.
Adequate end organ function as defined by:
11.1. total bilirubin < 1.5 x ULN,1 11.2. SGOT and SGPT < 2.5 x ULN, 11.3. creatinine < 1.5 x ULN, 11.4. Serum amylase and lipase ≤ 1.5 x ULN, 11.5. Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug. Women of child-bearing potential must agree to use adequate contraception, according to investigator's instructions.
Effective contraception must be in place :
- During the treatment with nilotinib
- Until 2 weeks after the end of treatment.
- Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication): 13.1. Potassium ≥ LLN, 13.2. Magnesium ≥ LLN, 13.3. Phosphorus, ≥ LLN, 13.4. Total calcium (corrected for serum albumin) ≥ LLN.
- Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).
Exclusion Criteria:
- Rectal tumors (up to 15 cm from the anus)
- Any metastasis.
- Performance status ECOG ≥ 3.
- Physical status score ASA ≥ 3.
Impaired cardiac function including any one of the following:
5.1. LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by locally read echocardiogram. 5.2. Inability to determine the QT interval on ECG. 5.3. Complete left bundle branch block. 5.4. Use of a ventricular-paced pacemaker. 5.5. Congenital long QT syndrome or a known family history of long QT syndrome. 5.6. History of or presence of clinically significant ventricular or atrial tachyarrhythmias. 5.7. Clinically significant resting bradycardia (< 50 beats per minute). 5.8. QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc. 5.9. History of clinically documented myocardial infarction. 5.10. History of unstable angina (during the last 12 months). 5.11. Other clinically significant heart disease (e.g. congestive heart failure or uncontrolled hypertension).
- Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
- History of significant congenital or acquired bleeding disorder unrelated to cancer.
- Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery.
- History of non-compliance to medical regimens or inability to grant consent.
- Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon).
- Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Patients actively receiving therapy with strong CYP3A4 inducers (e.g., dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John's Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).
- History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
- Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease.
- Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) female of childbearing potential unwilling to use contraceptive precautions throughout the trial and until two weeks after the end of treatment (post-menopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential). Contra-indication to nilotinib administration.
- Previous or current malignancies other than colon cancer within the last 5 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin.
- Emergency surgeries, including occlusion.
- Previous enrolment in the present study.
- Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Nilotinib
A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status.
Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days.
The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours).
When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
|
Each patient will receive nilotinib 800 mg/day every day for 7 days.
Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food.
The entire capsule should be swallowed with water.
No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach
Periodo de tiempo: Day 0
|
Day 0
|
ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach
Periodo de tiempo: Day 7
|
Day 7
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Efficacy of the 7day nilotinib treatment based on histological response as measured with tumour regression grade
Periodo de tiempo: Day 7
|
Day 7
|
Efficacy of the 7day nilotinib treatment based on histological response as measured with the proportion of tumour necrosis
Periodo de tiempo: Day 7
|
Day 7
|
Efficacy of the 7day nilotinib treatment based on histological response as measured with the type of tumour necrosis
Periodo de tiempo: Day 7
|
Day 7
|
Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v4.0 as assessed by CTCAE v4.0
Periodo de tiempo: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
Postoperative complications as assessed by Dindo and Clavien classification
Periodo de tiempo: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
Maximum Plasma Concentration [Cmax] of nilotinib .
Periodo de tiempo: Day 7, day 8
|
Day 7, day 8
|
Half-life of nilotinib
Periodo de tiempo: Day 7
|
Day 7
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IB 2015-03
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de colon
-
Hamamatsu UniversityDesconocidoCáncer gástrico | Cancer de pancreas | Cáncer de esófago | Cáncer de colonJapón
-
Chongqing Precision Biotech Co., LtdReclutamientoCáncer gástrico | Cancer de pancreas | Cáncer de esófago | Cáncer de recto | Cáncer de colonPorcelana
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkTerminadoCáncer gástrico | Cancer de pancreas | Cáncer de esófago | Cáncer de recto | Cáncer de colon | Cáncer hepatobiliarEstados Unidos
-
Scripps Translational Science InstituteTerminadoCancer de prostata | Cáncer de colonEstados Unidos
-
Barbara Ann Karmanos Cancer InstituteTerminadoCáncer colonrectal | Cancer de pancreas | Carcinoma de colon | Cáncer de páncreas | Neoplasia pancreática | Neoplasia maligna de intestino grueso | Cáncer de Colon | Tumor Maligno de ColonEstados Unidos
-
University of North Carolina, Chapel HillTerminadoCáncer colonrectal | Cancer de prostata | Cáncer de colonEstados Unidos
-
Baylor College of MedicineScott and White Hospital & ClinicTerminadoCáncer de pulmón | Cancer de prostata | Cáncer de colonEstados Unidos
-
Centre Hospitalier Universitaire de NīmesTerminadoCáncer de mama | Cancer de prostata | Cáncer de colonFrancia
-
Chungnam National University HospitalAtoGen Co. LtdReclutamientoCancer de pancreas | Cáncer de colonCorea, república de
-
Assistance Publique - Hôpitaux de ParisMSD FranceActivo, no reclutandoCáncer de mama | Neoplasias torácicas | Cáncer gástrico | Cancer de pancreas | Cáncer de ovarios | Cancer de prostata | Cáncer de vejiga | Cáncer de colonFrancia
Ensayos clínicos sobre Nilotinib
-
XSpray MicroparticlesTerminado
-
Georgetown UniversityDesconocidoEnfermedad de Parkinson | Enfermedad de Parkinson con demenciaEstados Unidos
-
Novartis PharmaceuticalsTerminadoHipertensión arterial pulmonarSuiza, Estados Unidos, Alemania, Singapur, Corea, república de, Canadá
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... y otros colaboradoresReclutamientoLeucemia mieloide crónica, fase crónica | NilotinibPorcelana
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActivo, no reclutandoTumor tenosinovial de células gigantes | Sinovitis villonodular pigmentada | Tumor de células gigantes de tipo difusoEstados Unidos
-
Novartis PharmaceuticalsYa no está disponibleSíndrome hipereosinofílico (SHE)
-
Novartis PharmaceuticalsTerminadoLeucemia mieloide crónicaAlemania
-
Hospital for Special Surgery, New YorkNovartis Pharmaceuticals; Rudolph Rupert Scleroderma ProgramTerminado
-
Novartis PharmaceuticalsTerminado
-
University Health Network, TorontoNovartisTerminadoSchwannomas vestibulares en crecimientoCanadá